DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma.
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma.
复制标题
循环白细胞中的 DNA 甲基化是多发性骨髓瘤的一种新型生物标志物。
DOI：
10.1038/s41409-022-01887-0
复制
发表时间：
2023
影响因子：
4.8
通讯作者：
Janz,Siegfried
中科院分区：
文献类型：
--
作者：
D'Souza,Anita;Brazauskas,Ruta;Teng,BiQing;Yun,Grant;Uttley,Hannah;Dong,Jing;Dwinell,MichaelB;Pasquini,MarceloC;Giralt,Sergio;Landau,Heather;Stadtmauer,Edward;Krishnan,Amrita;Janz,Siegfried
我们最近报告了多发性骨髓瘤（MM）患者接受标准治疗高剂量美法仑预处理、自体造血细胞移植（AHCT）和移植后来那度胺维持治疗后生活质量（QOL）恢复的长期轨迹[1]。我们发现，在移植后1年，达到疾病控制的MM幸存者恢复了癌症治疗功能评估-骨髓移植（FACT-BMT）评分，甚至超过了人群标准。尽管如此，许多患者在1年后继续经历中度至重度水平的症状负担[1]。虽然患者报告的结局（PRO）是确定的临床结局，但很少有研究探讨疾病过程中与已知生物标志物的关系。进行这样的研究可以帮助从机制上理解症状负担和以生物标志物为中心的治疗干预措施改善生活质量的潜力。大量证据表明循环白细胞DNA甲基化可用作癌症[2，3]、造血细胞移植[4]和成熟B细胞肿瘤自然史[5]的生物标志物。异常DNA甲基化对MM发生、进展和结局的影响也已得到充分证实[6]。因此，我们进行了一项辅助随访研究，旨在用DNA甲基化测量补充PRO。
We recently reported long-term trajectories of quality of life (QOL) recovery after standard-of-care high-dose melphalan conditioning, autologous hematopoietic cell transplantation (AHCT), and posttransplant lenalidomide maintenance in multiple myeloma (MM)[1]. We found that by 1 year post transplantation, MM survivors who achieved disease control recovered Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) scores, even exceeding population norms. Nonetheless, many patients continued to experience moderate to severe levels of symptom burden beyond 1 year [1].While patient-reported outcomes (PROs) are established clinical outcomes, few studies have explored relations with known biomarkers in disease processes. Conducting such research can aid in the mechanistic understanding of symptom burden and the potential for biomarker-focused therapeutic interventions to improve QOL. A large body of evidence exists on the utility of circulating leukocyte DNA methylation as a biomarker of cancer [2, 3], hematopoietic cell transplantation [4], and in the natural history of mature B-cell tumors [5]. The impact of aberrant DNA methylation on MM development, progression, and outcome is also well established [6]. Thus, we conducted an ancillary followup study aimed at complementing PROs with DNA methylation measurement.